First patient dosed in Cereno’s PAH trial
Cereno Scientific has dosed the first patient in EPIMODE, its global Phase IIb trial of the lead drug candidate CS1 in pulmonary arterial hypertension (PAH). This first dose formally launches the trial, which will evaluate CS1’s efficacy, optimal dose, safety, and tolerability, as well as its potential as a disease-modifying treatment.
The Gothenburg-based company activated the first clinical site in August 2026. More specialist PAH centers are now being activated across North America, Europe, and South America. Cereno expects up to 15 sites to be up and running by the end of 2026, and more than half of the planned global network by the end of the first quarter of 2027.
PAH is a serious, progressive disease in which structural changes in the blood vessels of the lungs increase resistance to blood flow and put growing strain on the right side of the heart. CS1 is being developed as an oral, once-daily add-on to standard care. It aims to address the mechanisms that drive disease progression, including vascular remodeling, fibrosis, and inflammation.
In the completed Phase IIa trial, CS1 met its primary endpoint, showing a favorable safety and tolerability profile. It also showed exploratory signs of efficacy, including improvements in right-heart function, functional class, and quality of life. A 12-month follow-on Expanded Access Program confirmed the safety profile.
The primary endpoint in EPIMODE is the change in pulmonary vascular resistance after nine months of treatment. After that period, patients are randomized again, so the trial can assess what happens when CS1 treatment is continued, started, or stopped. Patients who received placebo in the first period switch to CS1 in the second.
“Reaching first-patient dosing marks the transition from extensive preparations to randomized patient treatment. What makes CS1 particularly promising is its potential to offer a different approach to PAH treatment by targeting the underlying mechanisms that drive disease progression,” says Sten R. Sörensen, CEO of Cereno Scientific.
Cereno aims to complete patient recruitment in 2027 and report topline results in the fourth quarter of 2028. That timeline depends on how recruitment goes and on the company securing the financing it needs to run the trial as planned.
Published: November 19, 2026
